MIT Biotechnology Group

Longevity Fund + AGE1, Oct 18, 6-8 pm

Co-hosted by the MBG Entrepreneurship Initiative

The Longevity Fund and AGE1 in Boston

6:00 Seminar on aging research
6:30 Reception

More info here, but you MUST apply to attend with this easy form.

Laura Deming founded the Longevity Fund in 2011 as the first VC firm dedicated to funding high-potential longevity companies. So far, she’s raised $37M and has backed such companies as Unity Biotechnology, Precision Biosciences, System1, Decibel Therapeutics, and Elevian.
Building upon this success, Laura created the AGE1 Biotech accelerator to support early-stage, founder-driven companies that look to develop therapeutics which will extend the
human healthspan. AGE1’s 4-month program offers capital ($500K) and support to launch founder-driven biotech companies.

To apply for our next batch starting in January 2019, go to our website or contact us at

Leave a Reply